We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » French Drugmaker Sanofi Sees Delay in Diabetes Drug Launch
French Drugmaker Sanofi Sees Delay in Diabetes Drug Launch
The FDA has asked for more information on the pen injector device used in Sanofi and Zealand Pharma’s IGlarLixi combination product for diabetes, extending its review by three months.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor